메뉴 건너뛰기




Volumn 71, Issue 6, 2013, Pages 1395-1409

PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types

Author keywords

BRAF mutation; MEK inhibitor; NRAS mutation; PI3K inhibitor; PI3K AKT mTOR pathway; RAS RAF MEK ERK pathway

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; APITOLISIB; B RAF KINASE; BINDING PROTEIN; BUPARLISIB; COPANLISIB; DABRAFENIB; EVEROLIMUS; FK BINDING PROTEIN 12; G PROTEIN COUPLED RECEPTOR; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PIMASERTIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; TEMSIROLIMUS; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147;

EID: 84878652051     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2121-1     Document Type: Review
Times cited : (187)

References (105)
  • 1
    • 84855894652 scopus 로고    scopus 로고
    • Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
    • 22239440 10.1517/14728222.2011.645805 1:CAS:528:DC%2BC38Xos1Wktw%3D%3D
    • Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103-119
    • (2012) Expert Opin Ther Targets , vol.16 , pp. 103-119
    • Santarpia, L.1    Lippman, S.M.2    El-Naggar, A.K.3
  • 2
    • 68249093818 scopus 로고    scopus 로고
    • Targeting the phosphoinositide 3-kinase pathway in cancer
    • 19644473 10.1038/nrd2926 1:CAS:528:DC%2BD1MXpt1Wgtb4%3D
    • Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 627-644
    • Liu, P.1    Cheng, H.2    Roberts, T.M.3    Zhao, J.J.4
  • 4
    • 77949881462 scopus 로고    scopus 로고
    • The PI3K pathway as drug target in human cancer
    • 20085938 10.1200/JCO.2009.25.3641 1:CAS:528:DC%2BC3cXktF2lt7w%3D
    • Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
    • (2010) J Clin Oncol , vol.28 , pp. 1075-1083
    • Courtney, K.D.1    Corcoran, R.B.2    Engelman, J.A.3
  • 7
    • 79958026380 scopus 로고    scopus 로고
    • The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation
    • 21531565 10.1016/j.tibs.2011.03.006 1:CAS:528:DC%2BC3MXnsVOqs7k%3D
    • Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-328
    • (2011) Trends Biochem Sci , vol.36 , pp. 320-328
    • Mendoza, M.C.1    Er, E.E.2    Blenis, J.3
  • 9
    • 34547645033 scopus 로고    scopus 로고
    • Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer
    • 17671177 10.1158/0008-5472.CAN-06-4798 1:CAS:528:DC%2BD2sXosVemsb4%3D
    • Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP (2007) Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67:7106-7112
    • (2007) Cancer Res , vol.67 , pp. 7106-7112
    • Ma, L.1    Teruya-Feldstein, J.2    Bonner, P.3    Bernardi, R.4    Franz, D.N.5    Witte, D.6    Cordon-Cardo, C.7    Pandolfi, P.P.8
  • 10
    • 0033607633 scopus 로고    scopus 로고
    • Phosphorylation and regulation of Raf by Akt (protein kinase B)
    • 10576742 10.1126/science.286.5445.1741 1:CAS:528:DyaK1MXnsl2nsLk%3D
    • Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741-1744
    • (1999) Science , vol.286 , pp. 1741-1744
    • Zimmermann, S.1    Moelling, K.2
  • 11
    • 84856253626 scopus 로고    scopus 로고
    • Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance
    • 22260680 10.1042/BST20110609 1:CAS:528:DC%2BC38XhtFCqu7k%3D
    • Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40:139-146
    • (2012) Biochem Soc Trans , vol.40 , pp. 139-146
    • Aksamitiene, E.1    Kiyatkin, A.2    Kholodenko, B.N.3
  • 12
    • 79957983577 scopus 로고    scopus 로고
    • Targeting the PI3K/Akt/mTOR pathway - Beyond rapalogs
    • 21317449
    • Markman B, Dienstmann R, Tabernero J (2010) Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 1:530-543
    • (2010) Oncotarget , vol.1 , pp. 530-543
    • Markman, B.1    Dienstmann, R.2    Tabernero, J.3
  • 13
    • 79960605738 scopus 로고    scopus 로고
    • Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
    • 21547565 10.1007/s11523-011-0176-7
    • Ogita S, Lorusso P (2011) Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol 6:103-117
    • (2011) Target Oncol , vol.6 , pp. 103-117
    • Ogita, S.1    Lorusso, P.2
  • 15
    • 0037264633 scopus 로고    scopus 로고
    • Targeting RAS signalling pathways in cancer therapy
    • 12509763 10.1038/nrc969 1:CAS:528:DC%2BD38XpvVertbo%3D
    • Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22
    • (2003) Nat Rev Cancer , vol.3 , pp. 11-22
    • Downward, J.1
  • 18
    • 34547482919 scopus 로고    scopus 로고
    • Clinical experience of MEK inhibitors in cancer therapy
    • 17194493 10.1016/j.bbamcr.2006.11.009 1:CAS:528:DC%2BD2sXosFyksbs%3D
    • Wang D, Boerner SA, Winkler JD, LoRusso PM (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248-1255
    • (2007) Biochim Biophys Acta , vol.1773 , pp. 1248-1255
    • Wang, D.1    Boerner, S.A.2    Winkler, J.D.3    Lorusso, P.M.4
  • 23
    • 84878664337 scopus 로고    scopus 로고
    • First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology
    • 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr B163
    • Millham R, Houk B, Borzillo G, LoRusso P, Marburg L, Britten C, Wainberg Z, Adjei A, Grace D (2011) First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. In: Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics; 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr B163
    • (2011) Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
    • Millham, R.1    Houk, B.2    Borzillo, G.3    Lorusso, P.4    Marburg, L.5    Britten, C.6    Wainberg, Z.7    Adjei, A.8    Grace, D.9
  • 24
    • 84878664337 scopus 로고    scopus 로고
    • First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology
    • 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther Abstract nr A167
    • Millham R, Houk B, Borzillo G, Tabernero T, Bell-McGuinn K, Bendell J, Molina J, Kwakm E, Shapiro G (2011) First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. In: Proceedings of the AACR-NCI-eortc international conference: molecular targets and cancer therapeutics; 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr A167
    • (2011) Proceedings of the AACR-NCI-eortc International Conference: Molecular Targets and Cancer Therapeutics , vol.10 , Issue.11 SUPPL.
    • Millham, R.1    Houk, B.2    Borzillo, G.3    Tabernero, T.4    Bell-Mcguinn, K.5    Bendell, J.6    Molina, J.7    Kwakm, E.8    Shapiro, G.9
  • 27
    • 84855487013 scopus 로고    scopus 로고
    • A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    • 20127139 10.1007/s10637-010-9392-8 1:CAS:528:DC%2BC3MXhtVOrtL%2FN
    • Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY (2011) A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29:1021-1028
    • (2011) Invest New Drugs , vol.29 , pp. 1021-1028
    • Bennouna, J.1    Lang, I.2    Valladares-Ayerbes, M.3    Boer, K.4    Adenis, A.5    Escudero, P.6    Kim, T.Y.7    Pover, G.M.8    Morris, C.D.9    Douillard, J.Y.10
  • 28
    • 84864346162 scopus 로고    scopus 로고
    • A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
    • 21594619 10.1007/s10637-011-9687-4 1:CAS:528:DC%2BC38XmvFalsb8%3D
    • Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC (2012) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30:1216-1223
    • (2012) Invest New Drugs , vol.30 , pp. 1216-1223
    • Bodoky, G.1    Timcheva, C.2    Spigel, D.R.3    La Stella, P.J.4    Ciuleanu, T.E.5    Pover, G.6    Tebbutt, N.C.7
  • 31
    • 84863596086 scopus 로고    scopus 로고
    • MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
    • 22552284 10.1158/0008-5472.CAN-11-3747 1:CAS:528:DC%2BC38XpsFKktbk%3D
    • Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72:3228-3237
    • (2012) Cancer Res , vol.72 , pp. 3228-3237
    • Turke, A.B.1    Song, Y.2    Costa, C.3    Cook, R.4    Arteaga, C.L.5    Asara, J.M.6    Engelman, J.A.7
  • 32
    • 37249013214 scopus 로고    scopus 로고
    • National Institutes of Health (NIH) Accessed 11 Apr 2012
    • National Institutes of Health (NIH) (2012) ClinicalTrials.gov. http://clinicaltrials.gov. Accessed 11 Apr 2012
    • (2012) ClinicalTrials.gov
  • 33
    • 77953500567 scopus 로고    scopus 로고
    • Differences underlying EGFR and HER2 oncogene addiction
    • 20160489 10.4161/cc.9.5.11096 1:CAS:528:DC%2BC3cXht12ktb7M
    • Faber AC, Wong KK, Engelman JA (2010) Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 9:851-852
    • (2010) Cell Cycle , vol.9 , pp. 851-852
    • Faber, A.C.1    Wong, K.K.2    Engelman, J.A.3
  • 34
    • 79960052850 scopus 로고    scopus 로고
    • Ras in cancer and developmental diseases
    • 21779504 10.1177/1947601911411084 1:CAS:528:DC%2BC3MXpvFWlsbs%3D
    • Fernandez-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2:344-358
    • (2011) Genes Cancer , vol.2 , pp. 344-358
    • Fernandez-Medarde, A.1    Santos, E.2
  • 38
    • 58249120506 scopus 로고    scopus 로고
    • Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    • 19117997 10.1158/0008-5472.CAN-07-6656 1:CAS:528:DC%2BD1MXmvFer
    • Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G (2009) Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-150
    • (2009) Cancer Res , vol.69 , pp. 143-150
    • Ihle, N.T.1    Lemos, Jr.R.2    Wipf, P.3    Yacoub, A.4    Mitchell, C.5    Siwak, D.6    Mills, G.B.7    Dent, P.8    Kirkpatrick, D.L.9    Powis, G.10
  • 39
    • 84859412054 scopus 로고    scopus 로고
    • Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212
    • 22169769 10.1158/1535-7163.MCT-11-0505 1:CAS:528:DC%2BC38XjtlKisLw%3D
    • Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720-729
    • (2012) Mol Cancer Ther , vol.11 , pp. 720-729
    • Jing, J.1    Greshock, J.2    Holbrook, J.D.3    Gilmartin, A.4    Zhang, X.5    McNeil, E.6
  • 40
    • 66249116702 scopus 로고    scopus 로고
    • PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    • 19401449 10.1158/0008-5472.CAN-08-4765 1:CAS:528:DC%2BD1MXlvFWltLg%3D
    • Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286-4293
    • (2009) Cancer Res , vol.69 , pp. 4286-4293
    • Wee, S.1    Jagani, Z.2    Xiang, K.X.3    Loo, A.4    Dorsch, M.5    Yao, Y.M.6    Sellers, W.R.7    Lengauer, C.8
  • 41
    • 77951658161 scopus 로고    scopus 로고
    • KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
    • 20358631 10.1002/mc.20607 1:CAS:528:DC%2BC3cXktVCls7o%3D
    • Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, Kim TY (2010) KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49:353-362
    • (2010) Mol Carcinog , vol.49 , pp. 353-362
    • Yoon, Y.K.1    Kim, H.P.2    Han, S.W.3    Oh, D.Y.4    Im, S.A.5    Bang, Y.J.6    Kim, T.Y.7
  • 45
    • 80053307869 scopus 로고    scopus 로고
    • Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers
    • 21505228
    • Corcoran RB, Settleman J, Engelman JA (2011) Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2:336-346
    • (2011) Oncotarget , vol.2 , pp. 336-346
    • Corcoran, R.B.1    Settleman, J.2    Engelman, J.A.3
  • 46
    • 78649436372 scopus 로고    scopus 로고
    • BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
    • 21098728 10.1126/scisignal.2001148 1:CAS:528:DC%2BC3MXhs1SqtL4%3D
    • Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3:ra84
    • (2010) Sci Signal , vol.3 , pp. 84
    • Corcoran, R.B.1    Dias-Santagata, D.2    Bergethon, K.3    Iafrate, A.J.4    Settleman, J.5    Engelman, J.A.6
  • 50
    • 84862305656 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition
    • 22437314 10.1038/jid.2012.63 1:CAS:528:DC%2BC38Xjslemt7w%3D
    • Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H (2012) Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 132:1850-1859
    • (2012) J Invest Dermatol , vol.132 , pp. 1850-1859
    • Gowrishankar, K.1    Snoyman, S.2    Pupo, G.M.3    Becker, T.M.4    Kefford, R.F.5    Rizos, H.6
  • 55
    • 84862732834 scopus 로고    scopus 로고
    • Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations
    • 22389471 10.1158/1535-7163.MCT-11-0989 1:CAS:528:DC%2BC38Xltl2ntbY%3D
    • Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909-920
    • (2012) Mol Cancer Ther , vol.11 , pp. 909-920
    • Greger, J.G.1    Eastman, S.D.2    Zhang, V.3    Bleam, M.R.4    Hughes, A.M.5    Smitheman, K.N.6    Dickerson, S.H.7    Laquerre, S.G.8    Liu, L.9    Gilmer, T.M.10
  • 60
    • 79960946383 scopus 로고    scopus 로고
    • Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition
    • 21803746 10.1158/0008-5472.CAN-11-0140 1:CAS:528:DC%2BC3MXpsVOht7o%3D
    • Shi H, Kong X, Ribas A, Lo RS (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71:5067-5074
    • (2011) Cancer Res , vol.71 , pp. 5067-5074
    • Shi, H.1    Kong, X.2    Ribas, A.3    Lo, R.S.4
  • 62
    • 0348223934 scopus 로고    scopus 로고
    • NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
    • 14695152 1:CAS:528:DC%2BD3sXhtVSqurjM
    • Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-6488
    • (2003) Clin Cancer Res , vol.9 , pp. 6483-6488
    • Omholt, K.1    Platz, A.2    Kanter, L.3    Ringborg, U.4    Hansson, J.5
  • 66
    • 84856009717 scopus 로고    scopus 로고
    • Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
    • 22048237 10.1158/1078-0432.CCR-11-1491 1:CAS:528:DC%2BC38XhtVGqs70%3D
    • Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555-567
    • (2012) Clin Cancer Res , vol.18 , pp. 555-567
    • Kirkwood, J.M.1    Bastholt, L.2    Robert, C.3    Sosman, J.4    Larkin, J.5    Hersey, P.6    Middleton, M.7    Cantarini, M.8    Zazulina, V.9    Kemsley, K.10    Dummer, R.11
  • 68
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • 19188670 10.1200/JCO.2009.21.9170
    • Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096
    • (2009) J Clin Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3    Hamilton, S.R.4    Hammond, E.H.5    Hayes, D.F.6    McAllister, P.K.7    Morton, R.F.8    Schilsky, R.L.9
  • 69
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • 21163703 10.1016/S1470-2045(10)70209-6
    • De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594-603
    • (2011) Lancet Oncol , vol.12 , pp. 594-603
    • De Roock, W.1    De Vriendt, V.2    Normanno, N.3    Ciardiello, F.4    Tejpar, S.5
  • 72
  • 74
    • 84862026304 scopus 로고    scopus 로고
    • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    • 22446022 10.1016/j.ejca.2012.02.057 1:CAS:528:DC%2BC38XkvFSlsro%3D
    • Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466-1475
    • (2012) Eur J Cancer , vol.48 , pp. 1466-1475
    • Bokemeyer, C.1    Cutsem, E.V.2    Rougier, P.3    Ciardiello, F.4    Heeger, S.5    Schlichting, M.6    Celik, I.7    Kohne, C.H.8
  • 75
    • 18644378618 scopus 로고    scopus 로고
    • A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
    • 15967111 10.1593/neo.04532 1:CAS:528:DC%2BD2MXkvFeqtL0%3D
    • Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J (2005) A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7:336-347
    • (2005) Neoplasia , vol.7 , pp. 336-347
    • Wang, Y.1    Van Becelaere, K.2    Jiang, P.3    Przybranowski, S.4    Omer, C.5    Sebolt-Leopold, J.6
  • 78
    • 77956280407 scopus 로고    scopus 로고
    • PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
    • 20699365 10.1158/0008-5472.CAN-10-0409 1:CAS:528:DC%2BC3cXhtV2rsLbJ
    • Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70:6804-6814
    • (2010) Cancer Res , vol.70 , pp. 6804-6814
    • Halilovic, E.1    She, Q.B.2    Ye, Q.3    Pagliarini, R.4    Sellers, W.R.5    Solit, D.B.6    Rosen, N.7
  • 79
    • 70349878470 scopus 로고    scopus 로고
    • Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
    • 19637312 10.1002/ijc.24604 1:CAS:528:DC%2BD1MXhtFOkt77K
    • Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125:2332-2341
    • (2009) Int J Cancer , vol.125 , pp. 2332-2341
    • Balmanno, K.1    Chell, S.D.2    Gillings, A.S.3    Hayat, S.4    Cook, S.J.5
  • 81
    • 50949104555 scopus 로고    scopus 로고
    • Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
    • 18059185
    • Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A (2008) Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7:307-315
    • (2008) Cancer Biol Ther , vol.7 , pp. 307-315
    • Yu, K.1    Toral-Barza, L.2    Shi, C.3    Zhang, W.G.4    Zask, A.5
  • 82
    • 84859645779 scopus 로고    scopus 로고
    • The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
    • 22415236 10.1038/bjc.2012.70 1:CAS:528:DC%2BC38XlsFSktLg%3D
    • Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106:1386-1394
    • (2012) Br J Cancer , vol.106 , pp. 1386-1394
    • Haagensen, E.J.1    Kyle, S.2    Beale, G.S.3    Maxwell, R.J.4    Newell, D.R.5
  • 85
    • 79959328816 scopus 로고    scopus 로고
    • Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm
    • 21683865 10.1016/j.humpath.2011.03.003 1:CAS:528:DC%2BC3MXnslehtbo%3D
    • Kurman RJ, Shih I (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42:918-931
    • (2011) Hum Pathol , vol.42 , pp. 918-931
    • Kurman, R.J.1    Shih, I.2
  • 86
    • 1942469352 scopus 로고    scopus 로고
    • Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis
    • 15111296 10.1016/S0002-9440(10)63708-X 1:CAS:528:DC%2BD2cXns1Gqtb0%3D
    • Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518
    • (2004) Am J Pathol , vol.164 , pp. 1511-1518
    • Shih, I.1    Kurman, R.J.2
  • 89
    • 0027733796 scopus 로고
    • K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
    • 8342602 1:STN:280:DyaK3szktlaisA%3D%3D
    • Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
    • (1993) Am J Pathol , vol.143 , pp. 545-554
    • Hruban, R.H.1    Van Mansfeld, A.D.2    Offerhaus, G.J.3    Van Weering, D.H.4    Allison, D.C.5    Goodman, S.N.6    Kensler, T.W.7    Bose, K.K.8    Cameron, J.L.9    Bos, J.L.10
  • 92
    • 77954675751 scopus 로고    scopus 로고
    • Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer
    • 20642839 10.1186/1750-2187-5-10
    • Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5:10
    • (2010) J Mol Signal , vol.5 , pp. 10
    • Roy, S.K.1    Srivastava, R.K.2    Shankar, S.3
  • 95
    • 79151476662 scopus 로고    scopus 로고
    • Triple negative breast cancer: Unmet medical needs
    • 21161370 10.1007/s10549-010-1293-1 1:CAS:528:DC%2BC3MXhtVelsbw%3D
    • Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627-636
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 627-636
    • Pal, S.K.1    Childs, B.H.2    Pegram, M.3
  • 102
    • 84878642347 scopus 로고    scopus 로고
    • A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTor Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
    • Abstract 366
    • Britten C, Wainberg Z, Tabernero J, Alsina Maqueda M, Leong S, Sessa C, Millham R, Gallo J, Siu L, Brana I (2012) A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTor Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer. EORTC-NCI-AACR 2012 Abstract 366
    • (2012) EORTC-NCI-AACR 2012
    • Britten, C.1    Wainberg, Z.2    Tabernero, J.3    Alsina Maqueda, M.4    Leong, S.5    Sessa, C.6    Millham, R.7    Gallo, J.8    Siu, L.9    Brana, I.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.